Cancer Research Technology Ltd.
CRT is the technology transfer arm of Cancer Research UK, the largest cancer charity in the UK and the biggest single funding body for cancer research projects in Europe. The organization's primary remit is commercializing the IP generated by the £175 million ($274 million) of research funding that Cancer Research UK provides each year.
You may also be interested in...
Cancer Research Technology - the technology transfer arm of Cancer Research UK, the world's largest charity - has long moved beyond simply commercializing and managing the IP generated by the half billion in research funding provided by Cancer Research UK to five core research institutes across the UK, as well as to researchers at dozens of other universities and organizations. CRT has a growing, 85-strong in-house drug discovery capability which is being expanded with the help of a five-year, £7 million ($11 million) grant from Cancer Research UK - and it's this that lured in AstraZeneca and another industry collaborator, Cephalon.
Non-profit organizations' growing support for industry drug development does more than fill a funding gap. It brings disease-knowledge, patient-access and an understanding of the end-market that few traditional VCs can offer.
Roche could easily have swallowed cash-poor Antisoma whole. But the Swiss group has instead bought rights to the UK biotech's entire clinical portfolio, hoping thereby to preserve Antisoma's creativity--rather like it has done with Genentech.